The uptake of sEV-PD-L1 via sEVs by tumor cells protects against CD8 + T cell attacks, suggesting that inhibiting sEV-mediated PD-L1 distribution may enhance the effectiveness of anti-PD-L1 therapy in PCa [113]. The gene discussed is CD8A; the disease is posterior cortical atrophy.